Warren Grant Megnuson Clinical Center - NCI Clinical Trials Referral Office
Welcome,         Profile    Billing    Logout  
 11 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kreitman, Robert
NCT03340506 / 2017-001987-39: Dabrafenib and/or Trametinib Rollover Study

Recruiting
4
100
Europe, Japan, US, RoW
dabrafenib, trametinib
Novartis Pharmaceuticals
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma
12/27
12/27
NCT00321555: LMB-2 to Treat Hairy Cell Leukemia

Completed
2
15
US
Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
National Cancer Institute (NCI)
Hairy Cell Leukemia
08/16
12/22
NCT01981512: Study of Ibrutinib for Treatment of Relapsed Hairy Cell Leukemia

Recruiting
2
18
US
Ibrutinib
National Cancer Institute (NCI)
Hairy Cell Leukemia
05/17
05/17
NCT01059786: Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Checkmark P2 data in HCL
Nov 2011 - Nov 2011: P2 data in HCL
Active, not recruiting
2
69
US
Pentostatin, Nipent, Rituximab, Rituxan, Bendamustine, Bendeka, Treanda, Acetaminophen, Tylenol, Diphenhydramine, Benadryl, Epinephrine, Adrenaline, Antihistamines, Corticosteroids, Corticoid, Bronchodilators, Broncholytic, Intravenous (IV) Saline
National Cancer Institute (NCI)
Hairy Cell Leukemia
12/22
12/25
NCT04324112: Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Recruiting
2
45
US
binimetinib, Encorafenib
National Cancer Institute (NCI)
Hairy Cell Leukemia
04/28
07/28
NCT04322383 / 2019-000607-33: Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

Recruiting
2
40
US
binimetinib
National Cancer Institute (NCI)
Hairy Cell Leukemia
04/28
07/28
NCT00923013: Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

Checkmark P2 data in HCL
Nov 2011 - Nov 2011: P2 data in HCL
Active, not recruiting
2
203
US
Cladribine, Rituximab
National Cancer Institute (NCI)
Hairy Cell Leukemia
07/24
01/30
NCT06311227: Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Recruiting
2
20
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant
05/27
05/27
NCT00924170: Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

Completed
1/2
18
US
LMB-2, Fludarabine, Fludara, Cyclophosphamide, Cytoxan
National Cancer Institute (NCI)
Adult T-Cell Leukemia (ATL)
01/16
05/21
19-C-0042, NCT03805932: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Active, not recruiting
1
18
US
Moxetumomab Pasudotox-tdfk, Lumoxiti, Rituximab, Rituxan, Ruxience, Rituximab-pvvr, Dexamethasone, Ozurdex, Maxidex, DexPak 6 Day, Acetaminophen, Tylenol, Ofirmev, FeverAll, Diphenhydramine, Benadryl, Nytol, Banophen, Famotidine, Pepcid AC, Pepcid, Acid Controller, Aspirin, Ecotrin, Enteric Coated Aspirin, Buffered Aspirin
National Cancer Institute (NCI)
Hairy Cell Leukemia
07/23
06/25
NCT04815356: Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

Recruiting
1
27
US
CD22CART cell infusion
National Cancer Institute (NCI)
Hairy Cell Leukemia, Hairy Cell Leukemia Variant
12/36
12/36
NCT01087333: Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Recruiting
N/A
1263
US
National Cancer Institute (NCI)
Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Cutaneous T Cell Lymphoma (CTCL), Adult T Cell Lymphoma (ATL)
 
 
NCT04362865: Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection

Active, not recruiting
N/A
679
US
National Cancer Institute (NCI)
COVID-19
12/25
12/25

Download Options